Theratechnologies: tesamorelin data presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy 50th annual meeting
Montréal, Canada - September 13, 2010- Theratechnologies (TSX: TH) presented two scientific posters regarding tesamorelin, an investigational growth hormone-releasing factor being evaluated for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy
and currently under regulatory review by the U.S. Food and Drug Administration, at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ("ICAAC") meeting, in Boston, from Sunday, September 12, to Wednesday, September 15.
The first poster is entitled "Reduction in Visceral Adipose Tissue ("VAT") with Tesamorelin Correlates with Changes in Anthropometric, and Patient-Reported Outcome Parameters in HIV-infected Patients with Excess Abdominal Fat" and describes the correlations between VAT, waist circumference
and body image parameters in tesamorelin-treated patients.
The second poster is entitled "Efficacy and Long-Term Safety of Tesamorelin, a Growth Hormone-Releasing Factor Analogue, in Sub-Populations of HIV-Infected Patients with Excess Abdominal Fat" and describes the efficacy and safety of tesamorelin among different sub-populations of HIV-infected patients with excess abdominal fat.
Both posters were presented at the ICAAC poster session which took place on Sunday, September 12, from 11:30 a.m. to 1:30 p.m., and are now available on Theratechnologies' website at www.theratech.com
About HIV-Associated Lipodystrophy
Several factors including a patient's antiretroviral drug regimen and the HIV virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes. The changes in body composition may include excess abdominal fat accumulation, which is known as abdominal lipohypertrophy. There is currently no approved
treatment available for excess abdominal fat in HIV-infected patients with lipodystrophy.
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that discovers and develops innovative therapeutic products, with an emphasis on peptides, for commercialization. The Company targets unmet medical needs in specialty markets where it can retain all or part of the commercial rights to its products. Its most advanced
compound, tesamorelin, is an analogue of the human growth hormone releasing factor. In 2009, Theratechnologies submitted a New Drug Application to the U.S. Food and Drug Administration ("FDA"), seeking approval of tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The Company's
growth strategy is centered on the commercialization of tesamorelin in the United States through an agreement with EMD Serono, Inc. for HIV-associated lipodystrophy. Moreover, Theratechnologies' growth will also derive from the commercialization of tesamorelin in other markets for HIV-associated lipodystrophy, as
well as the development of clinical programs for tesamorelin in other medical conditions.
This press release contains certain statements that are considered "forward-looking information" within the meaning of applicable securities legislation. This forward-looking information includes, but is not limited to: information regarding the growth of Theratechnologies through the development of tesamorelin and additional clinical programs.
Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The assumptions made include
the assumption, among others, that the FDA will approve tesamorelin for commercial sale in the United States, the Company will enter into agreements with partners in geographies other than the United States and that results from additional clinical programs will be positive. These risks and uncertainties include, but are not
limited to: the risk that tesamorelin is not approved by the FDA for commercial sale in the United States, the risk that the Company is unable to conclude agreements with partners relating to tesamorelin in geographies other than the Unites States, or the risk that the design of clinical programs may not be begun or, if begun, must be suspended.
The Company refers potential investors to the "Risks and Uncertainties" section of its Annual Information Form (the "AIF") dated February 23, 2010. The AIF is available at www.sedar.com under the Company's public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking
statements. Forward-looking information reflects current expectations regarding future events and speaks only as of the date of this press release and represents the Company's expectations as of that date.
"Reproduced with permission - Theratechnologies "